The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model. Materials and Methods The effect of PP2 on radiosensitivity of U251 and T98G cells was investigated using clonogenic assays. The expression of E-cadherin, matrix metalloproteinases 2 (MMP2), Ephrin type-A receptor 2 (EphA2), and vascular endothelial growth factor (VEGF) was measured by Western blotting and an accumulation of !H2AX foci 6 hours after radiotherapy was measured after PP2 treatment. The effect of PP2 on migration, invasion, and vasculogenic mimicry formation (VMF) of U251 cells was evaluated. In an orthotopical brain tumor model with U251 cells, PP2 was injected intraperitoneally with or without oral TMZ before, during and after whole brain radiotherapy. Bioluminescence images were taken to visualize in vivo tumors and immunohistochemical staining of VEGF, CD31, EphA2, and hypoxia-inducible factor 1a was performed. Results PP2 increased radiosensitivity of U251 and T98G cells without decreasing survival of normal human astrocytes. Chemoradiotherapy with PP2 and TMZ resulted in increased accumulation of !H2AX foci. PP2 induced overexpression of E-cadherin and suppression of MMP2, VEGF, and EphA2. PP2 also compromised invasion, migration, and VMF of U251 cells. In brain tumors, chemoradiotherapy with PP2 and TMZ decreased tumor volume best, but not statistically significantly compared with chemoradiotherapy with TMZ. The expression of VEGF and CD31 was suppressed in PP2-treated tumors. Conclusion PP2 enhances radiosensitivity of malignant glioma cells and suppresses invasion and migration of U251 cells. Chemoradiotherapy with PP2 and TMZ resulted in non-significant tumor volume decrease.
Abstract
Purpose We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model. Materials and Methods The effect of PP2 on radiosensitivity of U251 and T98G cells was investigated using clonogenic assays. The expression of E-cadherin, matrix metalloproteinases 2 (MMP2), Ephrin type-A receptor 2 (EphA2), and vascular endothelial growth factor (VEGF) was measured by Western blotting and an accumulation of !H2AX foci 6 hours after radiotherapy was measured after PP2 treatment. The effect of PP2 on migration, invasion, and vasculogenic mimicry formation (VMF) of U251 cells was evaluated. In an orthotopical brain tumor model with U251 cells, PP2 was injected intraperitoneally with or without oral TMZ before, during and after whole brain radiotherapy. Bioluminescence images were taken to visualize in vivo tumors and immunohistochemical staining of VEGF, CD31, EphA2, and hypoxia-inducible factor 1a was performed. Results PP2 increased radiosensitivity of U251 and T98G cells without decreasing survival of normal human astrocytes. Chemoradiotherapy with PP2 and TMZ resulted in increased accumulation of !H2AX foci. PP2 induced overexpression of E-cadherin and suppression of MMP2, VEGF, and EphA2. PP2 also compromised invasion, migration, and VMF of U251 cells. In brain tumors, chemoradiotherapy with PP2 and TMZ decreased tumor volume best, but not statistically significantly compared with chemoradiotherapy with TMZ. The expression of VEGF and CD31 was suppressed in PP2-treated tumors. Conclusion PP2 enhances radiosensitivity of malignant glioma cells and suppresses invasion and migration of U251 cells. Chemoradiotherapy with PP2 and TMZ resulted in non-significant tumor volume decrease.
참고문헌 (25)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
- Masui K, "Review : molecular pathology in adult high-grade gliomas : from molecular diagnostics to target therapies", Neuropathol Appl Neurobiol, 38, pp.271~291 (2012)
- Hegi ME, "MGMT gene silencing and benefit from temozolomide in glioblastoma", N Engl J Med, 352, pp.997~1003 (2005)
- Angers-Loustau A, "SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions", Mol Cancer Res, 2, pp.595~605 (2004)
- Stehelin D, "Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization", Virology, 76, pp.675~684 (1977)
- Stettner MR, "Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells", Cancer Res, 65, pp.5535~5543 (2005)
- Du J, "Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy", Nat Biotechnol, 27, pp.77~83 (2009)
- Ding Q, "The pattern of enhancement of Src kinase activity on plateletderived growth factor stimulation of glioblastoma cells is affected by the integrin engaged", J Biol Chem, 278, pp.39882~39891 (2003)
- Jallal H, "A Src", Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo, 2007, pp.67, 1580~1588
- Park CM, "Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src", epidermal growth factor receptor-mediated p38, Akt signaling pathways, pp.Cancer Res, 2006[DOI]
- Rothschild SI, "Src inhibitors in lung cancer : current status and future directions", Clin Lung Cancer, 11, pp.238~242 (2010)
- Cuneo KC, "SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation", Int J Radiat Oncol Biol Phys, 64, pp.1197~1203 (2006)
- Kim IA, "Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6", Radiother Oncol, 92, pp.125~132 (2009)
- Lee KM, "microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling", Radiother Oncol, 101, pp.171~176 (2011)
- Fischer AH, "Cryosectioning tissues", CSH Protoc, 2008 (2008)
- Chahal M, "O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme", Mol Cancer Ther, 11, pp.2440~2450 (2012)
- Hanson JA, "Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme", Perm J, 17, pp.68~74 (2013)
- Wong ET, "Bevacizumab for recurrent glioblastoma multiforme : a metaanalysis", J Natl Compr Canc Netw, 9, pp.403~407 (2011)
- Huveldt D, "Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion", PLoS One, 8, pp.56505~ (2013)
- Le DM, "Exploitation of astrocytes by glioma cells to facilitate invasiveness : a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade", J Neurosci, 23, pp.4034~4043 (2003)
- Wilkinson DG, "Multiple roles of EPH receptors and ephrins in neural development", Nat Rev Neurosci, 2, pp.155~164 (2001)
- Wykosky J, "EphA2 as a novel molecular marker and target in glioblastoma multiforme", Mol Cancer Res, 3, pp.541~551 (2005)
- Zhou N, "Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endothelial cells", Microvasc Res, 82, pp.113~121 (2011)
- Zhuang G, "Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy", Cancer Res, 70, pp.299~308 (2010)
- Holen HL, "Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis", J Leukoc Biol, 84, pp.1183~1191 (2008)